Label-free drug discovery

Frontiers in Pharmacology

Volumn 5 MAR, Issue , 2014, Pages

  Fang, Ye ^a  

^a Biochemical Technologies Science and Technology Division Corning Incorporated ^*  (United States)

Author keywords

Cell phenotypic screen; Drug safety toxicity; Label free drug discovery; Lead selection; Molecular mechanism of action; Phenotypic screen; Polypharmacology; Target identification

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4,4' (2,2 DICHLOROETHENE 1,1 DIYL)BIS(2,6 DINITROPHENOL); ADENOSINE A2A RECEPTOR AGONIST; ANTINEOPLASTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ERLOTINIB; GEFITINIB; METHACHOLINE; MUSCARINIC M3 RECEPTOR; NITROPHENOL; TYRPHOSTIN; UNCLASSIFIED DRUG;

CARDIOTOXICITY; CELL COMPONENT; CELL KINETICS; CELL STRUCTURE; DRUG BINDING SITE; DRUG LABELING; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PHENOTYPE; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 84897936888     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00052     Document Type: Review

References (87)

1. Abassi, Y. A., Xi, B., Li, N., Ouyang, W., Seiler, A., Watzele, M., et al. (2012). Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. Br. J. Pharmacol. 165, 1424-1441. doi: 10.1111/j.1476-5381.2011.01623.x.
2. Abassi, Y. A., Xi, B., Zhang, W., Ye, P., Kirstein, S. L., Gaylord, M. R., et al. (2009). Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. Chem. Biol. 16, 712-723. doi: 10.1016/j.chembiol.2009.05.011.
3. Arrowsmith, J. (2011). Trial watch: phase II failures: 2008-2010. Nat. Rev. Drug Discov. 10, 328-329. doi: 10.1038/nrd3439.
4. Bagnaninchi, P. O., and Drummond, N. (2011). Real-time label-free monitoring of adipose-derived stem cell differentiation with electric cell-substrate impedance sensing. Proc. Natl. Acad. Sci. U.S.A. 108, 6462-6467. doi: 10.1073/pnas.1018260108.
5. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607. doi: 10.1038/nature11003.
6. Beher, D., Wu, J., Cumine, S., Kim, K. W., Lu, S. C., Atangan, L., et al. (2009). Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des. 74, 619-624. doi: 10.1111/j.1747-0285.2009.00901.x.
7. Bender, A., Scheiber, J., Glick, M., Davies, J. W., Azzaoui, K., Hamon, J., et al. (2007). Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. Chem. Med. Chem. 2, 861-873. doi: 10.1002/cmdc.200700026.
8. Bock, A., Chirinda, B., Krebs, F., Messerer, R., Bätz, J., Muth, M., et al. (2014). Dynamic ligand binding dictates partial agonism at a G protein-coupled receptor. Nat. Chem. Biol. 10, 18-20. doi: 10.1038/nchembio.1384.
9. Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., and Bork, P. (2008). Drug target identification using side-effect similarity. Science 321, 263-266. doi: 10.1126/science.1158140.
10. Carlsson, J., Coleman, R. G., Setola, V., Irwin, J. J., Fan, H., Schlessinger, A., et al. (2011). Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat. Chem. Biol. 7, 769-778. doi: 10.1038/nchembio.662.
11. Deng, H., and Fang, Y. (2012a). Discovery of nitrophenols as GPR35 agonists. Med. Chem. Comm. 3, 1270-1274. doi: 10.1039/C2MD20210G.
12. Deng, H., and Fang, Y. (2012b). Synthesis and agonistic activity at the GPR35 of 5,6-dihydroxyindole-2-carboxylic acid analogs. ACS Med. Chem. Lett. 3, 550-554. doi: 10.1021/ml300076u.
13. Deng, H., Hu, H., and Fang, Y. (2011a). Tyrphostin analogs are GPR35 agonists. FEBS Lett. 585, 1957-1962. doi: 10.1016/j.febslet.2011.05.026.
14. Deng, H., Hu, H., He, M., Hu, J., Niu, W., Ferrie, A. M., et al. (2011b). Discovery of 2-(4-methylfuran-2(5H)-ylidene)malononitrile and thieno[3,2-b]thiophene-2-carboxylic acid derivatives as G protein-coupled receptor-35 (GPR35) agonists. J. Med. Chem. 54, 7385-7396. doi: 10.1021/jm200999f.
15. Deng, H., Hu, H., and Fang, Y. (2012a). Multiple tyrosine metabolites are GPR35 agonists. Sci. Rep. 2, 373. doi: 10.1038/srep00373.
16. Deng, H., Wang, C., Su, M., and Fang, Y. (2012b). Probing biochemical mechanisms of action of muscarinic M3 receptor antagonists with label-free whole-cell assays. Anal. Chem. 84, 8232-8239. doi: 10.1021/ac301495n.
17. Deng, H., Sun, H., and Fang, Y. (2013a). Label-free cell phenotypic efficacy of agonists at endogenous muscarinic M3 receptor correlates with their residence time. J. Pharmacol. Toxicol. Methods 68, 323-333. doi: 10.1016/j.vascn.2013.07.005.
18. Deng, H., Wang, C., and Fang, Y. (2013b). Label-free cell phenotypic assessment of the molecular mechanism of action of epidermal growth factor receptor inhibitors. RSC Adv. 3, 10370-10378. doi: 10.1039/C3RA40426A.
19. Dodgson, K., Gedge, L., Murray, D. C., and Coldwell, M. (2009). A 100K well screen for a muscarinic receptor using the Epic label-free system-a reflection on the benefits of the label-free approach to screening seven-transmembrane receptors. J. Recept. Signal. Transduct. 29, 163-172. doi: 10.1080/10799890903079844.
20. Eggert, U. S. (2013). The why and how of phenotypic small-molecule screens. Nat. Chem. Biol. 9, 206-209. doi: 10.1038/nchembio.1206.
21. Eglen, R., and Reisine, T. (2011). Primary cells and stem cells in drug discovery: emerging tools for high-throughput screening. Assay Drug Dev. Technol. 9, 108-124. doi: 10.1089/adt.2010.0305.
22. Fang, Y. (2006). Label-free cell-based assays with optical biosensors in drug discovery. Assay Drug Dev. Technol. 4, 583-595. doi: 10.1089/adt.2006.4.583.
23. Fang, Y. (2010). Label-free receptor assays. Drug Discov. Today Technol. 7:e5-e11. doi: 10.1016/j.ddtec.2010.05.001.
24. Fang, Y. (2011a). The development of label-free cellular assays for drug discovery. Expert Opin. Drug Discov. 6, 1285-1298. doi: 10.1517/17460441.2012.642360.
25. Fang, Y. (2011b). Label-free biosensors for cell biology. Int. J. Electrochem. 2011:e460850. doi: 10.4061/2011/460850.
26. Fang, Y. (2012). Ligand-receptor interaction platforms and their applications for drug discovery. Expert Opin. Drug Discov. 7, 969-988. doi: 10.1517/17460441.2012.715631.
27. Fang, Y. (2013). Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery. J. Pharmacol. Toxicol. Methods 67, 69-81. doi: 10.1016/j.vascn.2013.01.004.
28. Fang, Y., and Ferrie, A. M. (2008). Label-free optical biosensor for ligand-directed functional selectivity acting on β2-adrenoceptor in living cells. FEBS Lett. 582, 558-564. doi: 10.1016/j.febslet.2008.01.021.
29. Fang, Y., Ferrie, A. M., Fontaine, N. H., Mauro, J., and Balakrishnan, J. (2006). Resonant waveguide grating biosensor for living cell sensing. Biophys. J. 91, 1925-1940. doi: 10.1529/biophysj.105.077818.
30. Fang, Y., Ferrie, A. M., Fontaine, N. H., and Yuen, P. K. (2005). Characteristics of dynamic mass redistribution of EGF receptor signaling in living cells measured with label free optical biosensors. Anal. Chem. 77, 5720-5725. doi: 10.1021/ac050887n.
31. Feng, Y., Mitchison, T. J., Bender, A., Young, D. W., and Tallarico, J. A. (2009). Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat. Rev. Drug Discov. 8, 567-578. doi: 10.1038/nrd2876.
32. Ferrie, A. M., Deichmann, O. D., Wu, Q., and Fang, Y. (2012). High resolution resonant waveguide grating imager for cell cluster analysis under physiological condition. Appl. Phys. Lett. 100, 223701. doi: 10.1063/1.4723691.
33. Ferrie, A. M., Sun, H., and Fang, Y. (2011). Label-free integrative pharmacology on-target of drugs at the β2-adrenergic receptor. Sci. Rep. 1, 33. doi: 10.1038/srep00033.
34. Ferrie, A. M., Sun, H., Zaytseva, N., and Fang, Y. (2014). Divergent label-free cell phenotypic pharmacology of ligands at the overexpressed β2-adrenergic receptors. Sci. Rep. 4, 3828. doi: 10.1038/srep03828.
35. Ferrie, A. M., Wang, C., Deng, H., and Fang, Y. (2013). Label-free optical biosensor with microfluidics identifies an intracellular signalling wave mediated through the β2-adrerengic receptor. Integr. Biol. 5, 1253-1261. doi: 10.1039/c3ib40112j.
36. Ferrie, A. M., Wu, Q., and Fang, Y. (2010). Resonant waveguide grating imager for live cell sensing. Appl. Phys. Lett. 97, 223704. doi: 10.1063/1.3522894.
37. Fu, H., Fu, W., Sun, M., Shou, Q., Zhai, Y., Cheng, H., et al. (2011). Kinetic cellular phenotypic profiling: prediction, identification, and analysis of bioactive natural products. Anal. Chem. 83, 6518-6526. doi: 10.1021/ac201670e.
38. Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., and Lau, K. W. (2012). Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575. doi: 10.1038/nature11005.
39. Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., et al. (2012). ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100-D1107. doi: 10.1093/nar/gkr777.
40. Goral, V., Jin, Y., Sun, H., Ferrie, A. M., Wu, Q., and Fang, Y. (2011). Agonist-directed desensitization of the β2-adrenergic receptor. PLoS ONE 6:e19282. doi: 10.1371/journal.pone.0019282.
41. Guo, D., Mulder-Krieger, T., Ijzerman, A. P., and Heitman, L. H. (2012). Functional efficacy of adenosine A2A receptor agonists is positively correlated to their receptor residence time. Br. J. Pharmacol. 166, 1846-1959. doi: 10.1111/j.1476-5381.2012.01897.x.
42. Hart, C. P. (2005). Finding the target after screening the phenotype. Drug Discov. Today 10, 513-519. doi: 10.1016/S1359-6446(05)03415-X.
43. Hennen, S., Wang, H., Peters, L., Merten, N., Simon, K., Spinrath, A., et al. (2013). Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist. Sci. Signal. 6, ra93. doi: 10.1126/scisignal.2004350.
44. Hoehndorf, R., Harris, M. A., Herre, H., Rustici, G., and Gkoutos, G. V. (2012). Semantic integration of physiology phenotypes with an application to the Cellular Phenotype Ontology. Bioinformatics 28, 1783-1789. doi: 10.1093/bioinformatics/bts250.
45. Hopkins, A. L. (2008). Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690. doi: 10.1038/nchembio.118.
46. Hu, H., Deng, H., and Fang, Y. (2012). Label-free phenotypic profiling identified D-luciferin as a GPR35 agonist. PLoS ONE 7:e34934. doi: 10.1371/journal.pone.0034934.
47. Irwin, J. J., and Shoichet, B. K. (2005). ZINC-a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45, 177-182. doi: 10.1021/ci049714.
48. Kamb, A., Wee, S., and Lengauer, C. (2007). Why is cancer drug discovery so difficult? Nat. Rev. Drug Discov. 6, 115-120. doi: 10.1038/nrd2155.
49. Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., and Shoichet, B. K. (2007). Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25, 197-206. doi: 10.1038/nbt1284.
50. Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., et al. (2009). Predicting new molecular targets for known drugs. Nature 462, 175-181. doi: 10.1038/nature08506.
51. Kenakin, T. (2009). Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat. Rev. Drug Discov. 8, 617-626. doi: 10.1038/nrd2838.
52. Kenakin, T. (2012). The potential for selective pharmacological therapies through biased receptor signaling. BMC Pharmacol. Toxicol. 13:3. doi: 10.1186/2050-6511-13-3.
53. Kepp, O., Galluzzi, L., Lipinski, M., Yuan, J., and Kroemer, G. (2011). Cell death assays for drug discovery. Nat. Rev. Drug Discov. 10, 221-237. doi: 10.1038/nrd3373.
54. Kholodenko, B. N. (2006). Cell signaling dynamics in time and space. Nat. Rev. Mol. Cell Biol. 7, 165-176. doi: 10.1038/nrm1838.
55. Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., et al. (2011). DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 39, D1035-D1041. doi: 10.1093/nar/gkq1126.
56. Koutsoukas, A., Simms, B., Kirchmair, J., Bond, P. J., Whitmore, A. V., Zimmer, S., et al. (2011). From in silico target prediction to multi-target drug design: current databases, methods and applications. J. Proteomics 74, 2554-2574. doi: 10.1016/j.jprot.2011.05.011.
57. Lee, J. A., Uhlik, M. T., Moxham, C. M., Tomandl, D., and Sall, D. J. (2012). Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J. Med. Chem. 55, 4527-4538. doi: 10.1021/jm201649s.
58. Levitzki, A., and Mishani, E. (2006). Tyrphostins and other tyrosine kinase inhibitors. Annu. Rev. Biochem. 75, 93-109. doi: 10.1146/annurev.biochem.75.103004.142657.
59. Lohse, M. J., and Calebiro, D. (2013). Cell biology: receptor signals come in waves. Nature 495, 457-458. doi: 10.1038/nature12086.
60. Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, S., Hamon, J., Jenkins, J. L., et al. (2012). Large-scale prediction and testing of drug activity on side-effect targets. Nature 486, 361-367. doi: 10.1038/nature11159.
61. McGuinness, R. (2007). Impedance-based cellular assay technologies: recent advances, future promise. Curr. Opin. Pharmacol. 7, 535-540. doi: 10.1016/j.coph.2007.08.004.
62. Morse, M., Sun, H., Tran, E., Levenson, R., and Fang, Y. (2013). Label-free integrative pharmacology ontarget of opioid ligands at the opioid receptor family. BMC Pharmacol. Toxicol. 14:17. doi: 10.1186/2050-6511-14-17.
63. Morse, M., Tran, E., Levension, R. L., and Fang, Y. (2011). Ligand-directed functional selectivity at the mu opioid receptor revealed by label-free on-target pharmacology. PLoS ONE 6:e25643. doi: 10.1371/journal.pone.0025643.
64. Pacholec, M., Bleasdale, J. E., Chrunyk, B., Cunningham, D., Flynn, D., Garofalo, R. S., et al. (2010). SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 285, 8340-8351. doi: 10.1074/jbc.M109.088682.
65. Pai, S., Verrier, F., Sun, H., Hu, H., Ferrie, A. M., Eshraghi, A., et al. (2012). Dynamic mass redistribution assay decodes differentiation of a neural progenitor stem cell. J. Biomol. Screen. 17, 1180-1191. doi: 10.1177/1087057112455059.
66. Pammolli, F., Magazzini, L., and Riccaboni, M. (2011). The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10, 428-438. doi: 10.1038/nrd3405.
67. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., et al. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214. doi: 10.1038/nrd3078.
68. Rask-Andersen, M., Almén, M. S., and Schiöth, H. B. (2011). Trends in the exploitation of novel drug targets. Nat. Rev. Drug Discov. 10, 579-590. doi: 10.1038/nrd3478.
69. Roth, B. L., Sheffler, D. J., and Kroeze, W. K. (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353-359. doi: 10.1038/nrd1346.
70. Scannell, J. W. (2012). Diagnosing the decline in pharamaceutical R&D efficiency. Nat. Rev. Drug Discov. 11, 191-200. doi: 10.1038/nrd3681.
71. Schenone, M., Danèík, V., Wagner, B. K., and Clemons, P. A. (2013). Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem. Biol. 9, 232-240. doi: 10.1038/nchembio.1199.
72. Schuck, P. (1997). Reliable determination of binding affinity and kinetics using surface plasmon resonance biosensors. Curr. Opin. Biotechnol. 8, 498-502. doi: 10.1016/S0958-1669(97)80074-2.
73. Seiler, K. P., George, G. A., Happ, M. P., Bodycombe, N. E., Carrinski, H. A., Norton, S., et al. (2008). ChemBank: a small-molecule screening and cheminformatics resource database. Nucleic Acids Res. 36, D351-D359. doi: 10.1093/nar/gkm843.
74. Shoemaker, R. H. (2006). The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6, 813-823. doi: 10.1038/nrc1951.
75. Shoichet, B. K., and Kobilka, B. K. (2012). Structure-based drug screening for G-protein-coupled receptors. Trends Pharmacol. Sci. 33, 268-272. doi: 10.1016/j.tips.2012.03.007.
76. Stevens, R. C., Cherezov, V., Katritch, V., Abagyan, R., Kuhn, P., Rosen, H., et al. (2012). The GPCR Network: a large-scale collaboration to determine human GPCR structure and function. Nat. Rev. Drug Discov. 12, 25-34. doi: 10.1038/nrd3859.
77. Swinney, D. C., and Anthony, J. (2011). How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507-519. doi: 10.1038/nrd3480.
78. Tran, E., and Fang, Y. (2008). Duplexed label-free G protein-coupled receptor assays for high throughput screening. J. Biomol. Screen. 13, 975-985. doi: 10.1177/1087057108326141.
79. Verdonk, E., Johnson, K., McGuinness, R., Leung, G., Chen, Y.-W., Tang, H. R., et al. (2006). Cellular dielectric spectroscopy: a label-free comprehensive platform for functional evaluation of endogenous receptors. Assays Drug Dev. Technol. 4, 609-619. doi: 10.1089/adt.2006.4.609.
80. Verrier, F., An, S., Ferrie, A. M., Sun, H., Kyoung, M., Deng, H., et al. (2011). GPCRs regulate the assembly of a multienzyme complex for purine biosynthesis. Nat. Chem. Biol. 7, 909-915. doi: 10.1038/nchembio.690.
81. Wang, Y., Xiao, J., Suzek, T. O., Zhang, J., Wang, J., and Bryant, S. H. (2009). PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 37, W623-W633. doi: 10.1093/nar/gkp456.
82. Welsh, M., Mangravite, L., Medina, M. W., Tantisira, K., Zhang, W., Huang, R. S., et al. (2009). Pharmacogenomic discovery using cell-based models. Pharmacol. Rev. 61, 413-429. doi: 10.1124/pr.109.001461.
83. Wermuth, C. G. (2004). Multitarget drugs: the end of the "one-target-one-disease" philosophy? Drug Discov. Today 9, 826-827. doi: 10.1016/S1359-6446(04)03213-1.
84. Wilke, R. A., Lin, D. W., Roden, D. M., Watkins, P. B., Flockhart, D., Zineh, I., et al. (2007). Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 6, 906-916. doi: 10.1038/nrd2423.
85. Yildirim, M. A., Goh, K. I., Cusick, M. E., Barabasi, A. L., and Vidal, M. (2007). Drug-target network. Nat. Biotechnol. 25, 1119-1126. doi: 10.1038/nbt1338.
86. Young, D. W., Bender, A., Hoyt, J., McWhinnie, E., Chirn, G. W., Tao, C. Y., et al. (2008). Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat. Chem. Biol. 4, 59-68. doi: 10.1038/nchembio.2007.53.
87. Ziegler, S., Pries, V., Hedberg, C., and Waldmann, H. (2013). Target identification for small bioactive molecules: finding the needle in the haystack. Angew. Chem. Int. Ed. Engl. 52, 2744-2792. doi: 10.1002/anie.201208749.